KRAS and cancer: The FOLFOX regimen used by the FOxTROT randomized control trial was reported as follows: oxaliplatin 85 mg/m2 + l-folinic acid 175 mg/m2 + fluorouracil 400 mg/m2; those patients with Kras wild-type cancers were sub-randomized with ± panitumumab 6mg/kg by IV bolus and 2400 mg/m2 by 46-h infusion.